News
and updates
News
and updatesODYSSEY team at Radboud receives the RIHS Societal Award 2020
March 2021
Contributions made by the ODYSSEY trial have not gone unnoticed and as a result, has earned researchers the Radboud Institute for Health Sciences Societal Impact Award.
ODYSSEY trial finds new drug is better for treating children living with HIV
March 2021
The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug anti-HIV combination. These results come from the ODYSSEY trial which was presented at the Conference
New European-African Project that will develop UNIVERSAL treatments for children living with HIV
UNIVERSAL, the newly funded European-African clinical research partnership will develop, evaluate and register two new antiretroviral formulations for infants and children newly diagnosed with HIV initiating antiretroviral therapy, and for children failing...
EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir
January, 2021
On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe.
Cheaper HIV treatment for children: a report in the Lancet
December, 2020
With the world engulfed by the COVID-19 pandemic, you may not have heard about some of the breakthroughs
European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV
November 2020
ODYSSEY trial data published in Lancet – shows increase in treatment options for older children living with HIV
August 2020
ODYSSEY trial data published in Lancet – shows increase in treatment options for older children living with HIV
Dolutegravir for Children living with HIV
Picturing Health have developed a short video explaining how dolutegravir, using preliminary data from the ODYSSEY trial, has gained approval for use in children.
ODYSSEY trial plays an important role in the FDA approval of dolutegravir for children – a big step towards timely access to optimal ART for children.
Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. FDA of the adult formulation for children weighing ≥20kg and dolutegravir dispersible tablets for children of 4 weeks of age and older.
What does COVID-19 mean for those living in HIV communities?
New videos have been developed by Picturing Health, to inform and promote behaviour that can reduce the spread of Coronavirus in Africa and South Asia